

Supporting Information

Fig S1. Subgroup analysis for TFR rate according to the duration of TKI treatment before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, m, months, 95% CI, 95% confidence interval.

Fig S2. Subgroup analysis for TFR rate according to deep molecular reaction (DMR) duration before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, m, months, 95% CI, 95% confidence interval.

Fig S3. Subgroup analysis for TFR rate according to gender before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval.

Fig S4. Subgroup analysis for TFR rate according to age before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval.

Fig S5. Subgroup analysis for TFR rate according to Sokal score before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval.

Fig S6. Subgroup analysis for TFR rate according to the depth of molecular reaction (MR) before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval.

Fig S7. Subgroup analysis for TFR rate according to types of TKI before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval, IMA, imatinib, NIL, nilotinib, DAS, dasatinib.

Fig S8. Subgroup analysis for TFR rate according to publish year before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval.

Fig S9. Subgroup analysis for TFR rate according to molecular relapse criteria before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, MMR, (loss of) major molecular response, 95% CI, 95% confidence interval.

Fig S1. Subgroup analysis for TFR rate according to the duration of TKI treatment before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, m, months, 95% CI, 95% confidence interval.




Fig S2. Subgroup analysis for TFR rate according to deep molecular reaction (DMR) duration before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, m, months, 95% CI, 95% confidence interval.




Fig S3. Subgroup analysis for TFR rate according to gender before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval.




Fig S4. Subgroup analysis for TFR rate according to age before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval.




Fig S5. Subgroup analysis for TFR rate according to Sokal score before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval.




Fig S6. Subgroup analysis for TFR rate according to depth of molecular reaction (MR) before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval.




Fig S7. Subgroup analysis for TFR rate according to types of TKI before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval, IMA, imatinib, NIL, nilotinib, DAS, dasatinib.




Fig S8. Subgroup analysis for TFR rate according to publish year before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, 95% CI, 95% confidence interval.




Fig S9. Subgroup analysis for TFR rate according to molecular relapse criteria before TKI discontinuation. TFR, treatment-free remission, TKI, tyrosine kinase inhibitor, MMR, (loss of) major molecular response, 95% CI, 95% confidence interval.

